Astellas’ Vaprisol Approved For “Water Poisoning” Indication
This article was originally published in The Pink Sheet Daily
Arginine vasopressin antagonist is the first drug indicated for the treatment of euvolemic hyponatremia.
You may also be interested in...
The hyponatremia drug is a selective vasopressin V2-receptor antagonist, like Astellas’ Vaprisol and Otsuka’s Samsca.
FDA has approved Astellas Pharma's Vaprisol (conivaptan) for the intravenous treatment of hospitalized patients with hypervolemic hyponatremia, the Japanese company announced March 2
Vasopressin antagonist clears FDA for treatment of hospitalized patients with hypervolemic hyponatremia.